IMPACT Therapeutics and Pharmanovia entered an exclusive partnership for the drug senaparib, granting rights in all 27 EU member states and Australia/New Zealand.
3 reports, 1 independent
Updated Jul 31
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IMPACT Therapeutics and Pharmanovia entered an exclusive partnership for the drug senaparib, granting rights in all 27 EU member states and Australia/New Zealand.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Citigroup involved in global financial markets; India and Canada aiming to close CEPA trade pact; Biocon arm seeks EMA CHMP approval for drug.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.